Last reviewed · How we verify

Paparid (BIETAMIVERINE)

Phase 2 active Small molecule

Paparid (generic name: BIETAMIVERINE) is a bietamiverine drug. It is currently in Phase 2 development.

Paparid works by blocking the M3 receptor, which helps to reduce smooth muscle contraction and glandular secretion.

Paparid (Bietamiverine) is a small molecule drug that targets the muscarinic acetylcholine receptor M3. It is a member of the bietamiverine drug class, but its commercial status, including whether it is patented or generic, and its approved indications are unknown. The mechanism of action of Paparid involves blocking the M3 receptor, which is involved in smooth muscle contraction and glandular secretion. As a result, Paparid may be used to treat conditions characterized by excessive smooth muscle contraction or glandular secretion. However, its safety and efficacy have not been established through FDA approval.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameBIETAMIVERINE
Drug classbietamiverine
TargetMuscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
ModalitySmall molecule
Therapeutic areaOther
PhasePhase 2

Mechanism of action

Imagine your body's muscles and glands are like a faucet - when the M3 receptor is turned on, the faucet opens and lets fluid flow. Paparid blocks this receptor, so the faucet stays closed and fluid doesn't flow as much. This can help to reduce symptoms in conditions where the muscles or glands are overactive.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paparid

What is Paparid?

Paparid (BIETAMIVERINE) is a bietamiverine drug.

How does Paparid work?

Paparid works by blocking the M3 receptor, which helps to reduce smooth muscle contraction and glandular secretion.

What is the generic name of Paparid?

BIETAMIVERINE is the generic (nonproprietary) name of Paparid.

What drug class is Paparid in?

Paparid belongs to the bietamiverine class. See all bietamiverine drugs at /class/bietamiverine.

What development phase is Paparid in?

Paparid is in Phase 2.

What does Paparid target?

Paparid targets Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 and is a bietamiverine.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing